Spark Therapeutics (Spark Therapeutics) Interest Expense : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Spark Therapeutics's interest expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Spark Therapeutics's Operating Income for the three months ended in Sep. 2019 was $ -68.66 Mil. Spark Therapeutics's Interest Expense for the three months ended in Sep. 2019 was $ 0.00 Mil. GuruFocus does not calculate Spark Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spark Therapeutics Interest Expense Historical Data

The historical data trend for Spark Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics Interest Expense Chart

Spark Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Interest Expense

Get a 7-Day Free Trial

Spark Therapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Spark Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Spark Therapeutics (NAS:ONCE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Spark Therapeutics's Interest Expense for the three months ended in Sep. 2019 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2019 was $-68.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2019 was $120.75 Mil.

Spark Therapeutics's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as

GuruFocus does not calculate Spark Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Spark Therapeutics (Spark Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104

Website

http://www.sparktx.com

Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.

Executives

Elliot Sigal	director
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster	officer: CHIEF FINANCIAL OFFICER	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga	officer: Chief Business Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth	director, officer: CHIEF SCIENTIFIC OFFICER	334 CR 692, BUFFALO GAP TX 79508
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd	10 percent owner	ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High	director, officer: See Remarks	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey	officer: Chief Operating Officer	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio	officer: Chief Commercial Officer	225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju	10 percent owner	565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025